Mesoblast Ltd has released a press release.
Submits New Information to FDA IND File for SR-aGVHD
Filed with ASX ·
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Earlier from Mesoblast
- MSB Annual Financial Results and Operational Highlights
- Preliminary Final Report
- US$45 Million Private Placement to Major Shareholders
- Reinstatement to Quotation
- Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE
Later from Mesoblast
- First Quarter Financial Results on Form 6-K
- MSB Q1 Financial Results and Operational Highlights
- Long-Term Survival for Acute GvHD Treatment with Remestemcel
- Extension of Undrawn US$30 million Facility
- Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast